RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
EyePoint Pharmaceuticals Stock

EyePoint Pharmaceuticals ROA 2024

EyePoint Pharmaceuticals ROA

-0.2

Ticker

EYPT

ISIN

US30233G2093

WKN

A2QJRU

In 2024, EyePoint Pharmaceuticals's return on assets (ROA) was -0.2, a -64.83% increase from the -0.57 ROA in the previous year.

EyePoint Pharmaceuticals Aktienanalyse

What does EyePoint Pharmaceuticals do?

EyePoint Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development and marketing of innovative products targeting medical and eye-related conditions. The company was founded in 1987 and is headquartered in Watertown, Massachusetts. EyePoint Pharmaceuticals has a diverse portfolio of products focused on the treatment of eye diseases. This includes products for the treatment of retinal diseases such as diabetic retinopathy, macular degeneration, and retinal vein occlusions, as well as products for preventing postoperative infections and relieving pain after eye surgeries. The business model of EyePoint Pharmaceuticals is based on the development and marketing of drugs and technologies tailored to the needs of patients and physicians in the field of ophthalmology. The company aims to improve patients' quality of life by offering innovative, safe, and effective products of the highest quality. One of EyePoint Pharmaceuticals' key technologies is the Durasert technology, which allows for controlled release of drugs over an extended period of time. This technology is utilized in many of the company's products, such as the Iluvien implant for treating diabetic retinopathy and macular degeneration. The company operates in various sectors, including ophthalmology, pain management, and ophthalmology. Each of these sectors has its own products and technologies tailored specifically to the needs of patients and physicians in those areas. A significant factor in EyePoint Pharmaceuticals' business model is partnerships with other companies and organizations that support collaboration in the development and marketing of new products. One such partnership is the joint venture with Ocumension Therapeutics, which aims to market EyePoint Pharmaceuticals' products in the Asian market. Overall, the company has introduced a variety of innovative products to the market that have had a significant impact on ophthalmology. These include products such as the Ozurdex implant for treating macular degeneration and uveitis, as well as the Dexycu injection for preventing postoperative inflammation and pain. In recent years, the company has made progress in the development of drugs for retinal diseases such as diabetic retinopathy and retinal vein occlusions. One such development is the Yutiq implant, specifically designed to slow the progression of diabetic retinopathy. Overall, EyePoint Pharmaceuticals has a significant influence on ophthalmology and plays a crucial role in the development of innovative products and technologies to improve patients' quality of life. The company will continue to play an important role in the medical industry by focusing on the development and marketing of products targeting specific needs of patients and physicians in the field of ophthalmology. EyePoint Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding EyePoint Pharmaceuticals's Return on Assets (ROA)

EyePoint Pharmaceuticals's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing EyePoint Pharmaceuticals's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider EyePoint Pharmaceuticals's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in EyePoint Pharmaceuticals’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about EyePoint Pharmaceuticals stock

What is the Return on Assets (ROA) of EyePoint Pharmaceuticals this year?

The Return on Assets (ROA) of EyePoint Pharmaceuticals is -0.2 undefined this year.

What was the ROA of EyePoint Pharmaceuticals compared to the previous year?

The ROA of EyePoint Pharmaceuticals has increased by -64.83% compared to the previous year.

What consequences do high ROA have for investors of EyePoint Pharmaceuticals?

A high ROA is advantageous for investors of EyePoint Pharmaceuticals, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in EyePoint Pharmaceuticals?

A low ROA can be unfavorable for investors of EyePoint Pharmaceuticals as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of EyePoint Pharmaceuticals affect the company?

An increase in ROA of EyePoint Pharmaceuticals can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of EyePoint Pharmaceuticals impact the company?

A reduction in the ROA of EyePoint Pharmaceuticals can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of EyePoint Pharmaceuticals?

Some factors that can influence the ROA of EyePoint Pharmaceuticals include revenue, operating costs, asset structure, and industry average.

Why is the ROA of EyePoint Pharmaceuticals important for investors?

The ROA of EyePoint Pharmaceuticals is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can EyePoint Pharmaceuticals take to improve ROA?

To improve ROA, EyePoint Pharmaceuticals can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does EyePoint Pharmaceuticals pay?

Over the past 12 months, EyePoint Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, EyePoint Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of EyePoint Pharmaceuticals?

The current dividend yield of EyePoint Pharmaceuticals is .

When does EyePoint Pharmaceuticals pay dividends?

EyePoint Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of EyePoint Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is EyePoint Pharmaceuticals located?

EyePoint Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von EyePoint Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of EyePoint Pharmaceuticals from 8/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/26/2024.

When did EyePoint Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/26/2024.

What was the dividend of EyePoint Pharmaceuticals in the year 2023?

In the year 2023, EyePoint Pharmaceuticals distributed 0 USD as dividends.

In which currency does EyePoint Pharmaceuticals pay out the dividend?

The dividends of EyePoint Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von EyePoint Pharmaceuticals

Our stock analysis for EyePoint Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EyePoint Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.